Effects of Medisinstart for Type 2 Diabetes

NCT ID: NCT06273657

Last Updated: 2024-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-07

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist. The aim of the service is to promote correct medication use and increase patient adherence. The effect of Medisinstart has previously been studied among patients starting a new cardiovascular drug. The aim of the project is to map the effects of Medisinstart among patients starting a new medication for type 2 diabetes. Knowledge about the effects of Medisinstart is important in order to maximize the benefits of the service for patients and society. The project is being conducted as a randomized controlled trial among adult patients starting a new medication for type 2 diabetes. The intervention group receives Medisinstart, while the control group only receives prescription dispensing as normal. Data collection includes HbA1c analysis in blood samples and responses to questionnaires. HbA1c is an established measure of glycemic control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Medisinstart

Group Type EXPERIMENTAL

Medisinstart

Intervention Type OTHER

Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.

Control

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medisinstart

Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up consultations with a pharmacist.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Extracted a new drug/active substance (A10A/A10B) for type 2 diabetes
* Age ≥ 18 years
* The drugs are administered by the patient/relatives
* Good command of Norwegian, both written and spoken

Exclusion Criteria

* Inability to understand and/or complete consent forms, questionnaires and/or other patient-oriented materials
* Not able to attend physical appointments in the pharmacy
* Not given written consent to participate in the study
* Diabetes medication is administered by a healthcare professional
* Known pregnancy
* HbA1c is unsuitable as an average measure of blood glucose at baseline
* Received initiation of medication for type 2 diabetes within the last year
* Ongoing participation in other studies involving similar interventions to increase adherence and ensure correct medication use
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Norwegian Pharmacy Association

OTHER

Sponsor Role collaborator

Apokus AS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sara Bremer, PhD

Role: PRINCIPAL_INVESTIGATOR

Head of Research and Development

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ryfylke apotek

Rennesøy, Rennesøy, Norway

Site Status RECRUITING

Apotek 1 Veakrossen

Veavåg, Veavåg, Norway

Site Status RECRUITING

Vitusapotek Åfjord

Åfjord, , Norway

Site Status RECRUITING

Apotek 1 Andslimoen

Bardufoss, , Norway

Site Status RECRUITING

Apotek 1 Brandbu

Brandbu, , Norway

Site Status RECRUITING

Apotek 1 Brummundal

Brumunddal, , Norway

Site Status RECRUITING

Sykehusapoteket i Drammen

Drammen, , Norway

Site Status RECRUITING

Vitusapotek Gjøvik

Gjøvik, , Norway

Site Status RECRUITING

Vitusapotek Jessheim

Jessheim, , Norway

Site Status RECRUITING

Boots apotek Kløfta

Kløfta, , Norway

Site Status RECRUITING

Vitusapotek Leksvik

Leksvik, , Norway

Site Status RECRUITING

Apotek 1 Lena

Lena, , Norway

Site Status RECRUITING

Boots apotek Loddefjord

Loddefjord, , Norway

Site Status RECRUITING

Sykehusapoteket i Oslo, Aker

Oslo, , Norway

Site Status RECRUITING

Vitusapotek Røa

Oslo, , Norway

Site Status RECRUITING

Vitusapotek Jekta

Tromsø, , Norway

Site Status RECRUITING

Sykehusapoteket i Trondheim

Trondheim, , Norway

Site Status RECRUITING

Vitusapotek Ulefoss

Ulefoss, , Norway

Site Status RECRUITING

Boots apotek Linnea

Øystese, , Norway

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Norway

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sara Bremer, PhD

Role: CONTACT

Karine Wabø Ruud, PhD

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Apokus-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pharmacists Management of Diabetes
NCT00869076 COMPLETED PHASE4
Community Pharmacy Produce Prescriptions
NCT06920355 NOT_YET_RECRUITING NA